• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

作者信息

Kang Jin, Chen Hua-Jun, Wang Zheng, Liu Jing, Li Bing, Zhang Tengfei, Yang Zhenfan, Wu Yi-Long, Yang Jin-Ji

机构信息

Guangdong Cardiovascular Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.

出版信息

J Thorac Oncol. 2018 Apr;13(4):e49-e53. doi: 10.1016/j.jtho.2017.10.028. Epub 2017 Nov 8.

DOI:10.1016/j.jtho.2017.10.028
PMID:29128427
Abstract
摘要

相似文献

1
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.奥希替尼与卡博替尼联合治疗一名对克唑替尼耐药后出现多个MET二次位点突变的EGFR突变型肺腺癌患者
J Thorac Oncol. 2018 Apr;13(4):e49-e53. doi: 10.1016/j.jtho.2017.10.028. Epub 2017 Nov 8.
2
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.在EGFR突变的非小细胞肺癌中，T790M阳性后相继出现MET扩增时，全剂量克唑替尼与奥希替尼联合使用的耐受性及有效性
J Thorac Oncol. 2017 Jul;12(7):e85-e88. doi: 10.1016/j.jtho.2017.02.020. Epub 2017 Mar 6.
3
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.MET 扩增型非小细胞肺癌患者奥希替尼耐药的下一代测序临床分析。
Lung Cancer. 2018 Apr;118:105-110. doi: 10.1016/j.lungcan.2018.02.007. Epub 2018 Feb 13.
4
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.Sunvozertinib克服携带EGFR外显子18 DelE709_T710insD突变的肺腺癌对阿法替尼和奥希替尼的耐药性。
J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y.
5
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.携罕见 EGFR L747P 突变的非小细胞肺癌对吉非替尼和奥希替尼（AZD9291）均表现出内在耐药性：一例报告。
Thorac Cancer. 2018 Jun;9(6):745-749. doi: 10.1111/1759-7714.12637. Epub 2018 Apr 19.
6
Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma.奥希替尼剂量递增可诱导进展性EGFR T790M突变型柔脑膜肺腺癌消退。
J Thorac Oncol. 2017 Nov;12(11):e188-e190. doi: 10.1016/j.jtho.2017.07.029.
7
Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.克唑替尼治疗期间 MET 扩增三阴性乳腺癌进展时获得对卡博替尼敏感的 MET D1228N 突变。
Clin Breast Cancer. 2020 Aug;20(4):e433-e438. doi: 10.1016/j.clbc.2020.02.003. Epub 2020 Feb 19.
8
Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.在对阿法替尼和克唑替尼联合治疗敏感的肺腺癌中鉴定出一种与EGFR突变共存的新型MET外显子14跳跃变体
J Thorac Oncol. 2019 Apr;14(4):e70-e72. doi: 10.1016/j.jtho.2018.11.026.
9
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.肺腺癌中一种新型获得性外显子 20 EGFR M766Q 突变介导奥希替尼耐药，但对奈拉替尼和波齐替尼敏感。
J Thorac Oncol. 2019 Nov;14(11):1982-1988. doi: 10.1016/j.jtho.2019.06.015. Epub 2019 Jun 27.
10
Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.携带EGFR突变和BRAF V600E的肺腺癌对奥希替尼和维莫非尼联合用药有反应，可克服奥希替尼耐药性。
Clin Lung Cancer. 2021 May;22(3):e390-e394. doi: 10.1016/j.cllc.2020.06.008. Epub 2020 Jun 11.

引用本文的文献

1
A Phase II Study of Cabozantinib in Patients With -Altered Lung Cancers.卡博替尼用于治疗特定改变的肺癌患者的II期研究。
JTO Clin Res Rep. 2025 Jun 5;6(8):100857. doi: 10.1016/j.jtocrr.2025.100857. eCollection 2025 Aug.
2
A novel mesenchymal epithelial transition (MET) inhibitor, CB538, relieves acquired resistance in -mutated -amplified non-small cell lung cancer.一种新型间充质上皮转化（MET）抑制剂CB538可缓解EGFR突变、EGFR扩增的非小细胞肺癌中的获得性耐药。
Transl Cancer Res. 2025 Mar 30;14(3):1915-1927. doi: 10.21037/tcr-24-1614. Epub 2025 Mar 24.
3
REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?
REGN5093-M114：一种抗体药物偶联物能否克服非小细胞肺癌中对表皮生长因子受体和间充质上皮转化酪氨酸激酶抑制剂耐药的挑战？
Transl Lung Cancer Res. 2024 Aug 31;13(8):2082-2086. doi: 10.21037/tlcr-24-144. Epub 2024 Jul 26.
4
Mutation of as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with Mutation.作为非小细胞肺癌中具有**某种突变**的克唑替尼耐药的一种获得性潜在机制的**该突变**。 备注：原文中两个mutation指代不明，我按照字面进行了翻译，翻译出来的句子读起来不通顺，建议你检查下原文是否准确完整。
Lung Cancer (Auckl). 2024 Aug 27;15:123-128. doi: 10.2147/LCTT.S467584. eCollection 2024.
5
Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.Savolitinib 使 D1228H 突变诱导的克唑替尼耐药 MET 外显子 14 跳跃突变型肺腺癌患者获得敏感性。
J Cancer Res Clin Oncol. 2024 Aug 24;150(8):395. doi: 10.1007/s00432-024-05920-1.
6
Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein-Ligand Interactions and High Selectivity.筛选超大编码化合物库可导致新的蛋白质-配体相互作用和高选择性。
J Med Chem. 2024 Jan 25;67(2):864-884. doi: 10.1021/acs.jmedchem.3c01861. Epub 2024 Jan 10.
7
Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo Amplification in Patients with Metastatic -Mutated NSCLC.针对转移性 - 突变型 NSCLC 患者获得性和从头扩增的 EGFR-TKI 和克唑替尼联合治疗的真实世界数据。
Int J Mol Sci. 2023 Aug 23;24(17):13077. doi: 10.3390/ijms241713077.
8
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.简短报告：表皮生长因子受体（EGFR）突变且间充质上皮转化因子（MET）扩增的非小细胞肺癌患者对奥希替尼联合MET抑制剂的临床反应、毒性及耐药机制
JTO Clin Res Rep. 2023 Jun 1;4(8):100533. doi: 10.1016/j.jtocrr.2023.100533. eCollection 2023 Aug.
9
Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach.对分离出的海洋真菌代谢产物作为抗癌剂的分子与生物学研究：一种多靶点方法
Metabolites. 2023 Jan 21;13(2):162. doi: 10.3390/metabo13020162.
10
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.非小细胞肺癌中 MET 酪氨酸激酶结构域的突变与酪氨酸激酶抑制剂耐药性。
Respir Res. 2023 Jan 25;24(1):28. doi: 10.1186/s12931-023-02329-1.